Tyrosine kinase inhibitors concentration monitoring in chronic myeloid leukemia

Leuk Res. 2010 Jun;34(6):698-9. doi: 10.1016/j.leukres.2009.12.009. Epub 2010 Jan 13.
No abstract available

Publication types

  • Comment
  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacokinetics
  • Blood Chemical Analysis / methods
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism
  • Monitoring, Physiologic* / methods
  • Osmolar Concentration
  • Patient Compliance
  • Protein Kinase Inhibitors / administration & dosage
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / blood*
  • Protein Kinase Inhibitors / pharmacokinetics
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Protein-Tyrosine Kinases